Home › Bioproduction
Bioproduction Market Research Reports & Consulting
Market Reports
| Title | Published | Price | TOC Available |
|---|---|---|---|
Biologics Safety Testing Market by Product (Instruments, Services, Kits & Reagents), Test (Endotoxin, Sterility Test, Cell Line Authentication, Bioburden), Application (Vaccine Development, Blood Products, Stem Cell Research) - Global Forecast to 2022Biologics safety testing is a mandatory process in pharmaceutical and biotechnological companies. It is used as a quality control measure for the drug development process. The biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% from 2017 to 2022. The top four players in this market are Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany) and SGS SA (Switzerland) are. These companies have a broad product & service portfolio with comprehensive features and have a strong geographical presence. |
July 2017 | $ 5650 |
|
Mycoplasma Testing Market by Product & Services (Kits & Reagent and Instruments), Technique (PCR, ELSA, Enzymatic Methods, and DNA Staining), Application (Cell Line Testing and Virus Testing), End User (Pharmaceutical Companies and Cell Banks) - Global Forecast to 2022The mycoplasma testing market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5%. The base year considered for the report is 2016. Key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd., WuXi AppTec (U.S.), Norgen Biotek Corp. (Canada), Agilent Technologies (U.S.), Biotools, B & M Labs, S.A (Spain), Eurofins Scientific (Luxembourg), Gibraltar Laboratories (U.S.), GeneCopoeia, Inc. (U.S.), GenBio (Canada), Hylabs (Israel), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (U.S.), Sartorius AG (Germany), Savyon Diagnostics (Israel), and ScienCell Research Laboratories, Inc. (Canada). |
June 2017 | $ 5650 |
|
High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) - Global Forecast to 2021The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US). |
April 2017 | $ 5650 |
|
Downstream Processing Market by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract Manufacturing Organization) - Global Forecast to 2021The global downstream processing market is projected to reach USD 22.03 Billion by 2021 from USD 10.32 Billion in 2016, at a CAGR of 16.4% from 2016 to 2021. In this report, the global downstream processing market is broadly segmented on the basis of technique, product, application, end user, and region. |
March 2017 | $ 5650 |
|
3D Bioprinting Market by Technology (Microextrusion, Inkjet, Laser, Magnetic), Material (Cells, Hydrogels, Extracellular Matrices, Biomaterials), Application (Clinical (Bone, Cartilage, Skin) & Research (Regenerative Medicine)) - Global Forecasts to 2021The 3D bioprinting market is expected to reach USD 1,332.6 Million by 2021 from USD 411.4 Million in 2016, at a CAGR of 26.5% during the forecast period. Rising demand for organ transplantation, growing R&D, increasing public and private investments in research, and rising use of 3D bioprinting in drug discovery are driving the growth of this market. However, a lack of complete automation in 3D bioprinting and socio-ethical concerns related to the use of 3D-bioprinted products are the major challenges in this market. |
January 2017 | $ 5650 |
|
Pyrogen Testing Market by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), Test (In Vitro, Lal, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021The global pyrogen testing market is valued at USD 610.2 Million in 2016 and is expected to grow at a CAGR of 12.2%, to reach USD 1086.3 Million by 2021. Pyrogen testing is important and mandatory step in the manufacturing process to remove or inactivate potential bacterial toxins. Pyrogen testing product are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc., is on a rise. |
August 2016 | $ 5650 |
|
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.
Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement
Connect With Us
Live Chat Support
Search reports
'Connect With Us
